John Mascarenhas

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, John Mascarenhas sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 1 currently recruiting 7 completed early-phase tilt top decile by trial count

John Mascarenhas: 11 sponsored US clinical trials, 1 recruiting.

John Mascarenhas sponsors 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Post-Essential Thrombocythemia Myelofibrosis, with 2 trials.

Top-decile sponsor footprint

John Mascarenhas ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 2

Study of Canakinumab in Patients With Myelofibrosis

NCT05467800
NOT YET RECRUITING Phase 2

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

NCT07447817
COMPLETED Phase 2

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

NCT04281498
COMPLETED Phase 1

MPN-RC 118 AVID200 in Myelofibrosis

NCT03895112
COMPLETED Phase 2

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

NCT03065400
COMPLETED Phase 1

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

NCT02407080
COMPLETED Phase 1

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

NCT02076191
TERMINATED Phase 2

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

NCT01790295
COMPLETED Phase 1

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

NCT01693601
TERMINATED Phase 1

Anti-TGF-beta Therapy in Patients With Myelofibrosis

NCT01291784
COMPLETED Phase 2

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

NCT00572897

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 6

Therapeutic Areas

Post-Essential Thrombocythemia Myelofibrosis 2
Primary Myelofibrosis 2
Post ET MF 1
PV-MF 1
Post-polycythemia Vera Related Myelofibrosis 1
ET-MF 1
Post-PV MF 1
Post-Polycythemia Vera Myelofibrosis 1

What is open in the John Mascarenhas pipeline

1 recruiting of 11 indexed (9% open); 7 completed (64%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Post-Essential Thrombocythemia Myelofibrosis (2 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

John Mascarenhas: open-pipeline peers nationwide

Peers matched on 11 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

John Mascarenhas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%2%4%6%8%10% Total trials Recruiting share John MascarenhasAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeAlkermesDBV TechnologiesFlorida Gulf Coast UniversityGenfit
John Mascarenhas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

John Mascarenhas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this John Mascarenhas page

11 registered trials is a research-attention snapshot, not an endorsement of John Mascarenhas or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

John Mascarenhas pipeline card: 11 registered trials from official public datasets.Report a data error.